(NASDAQ: ADAP) Adaptimmune Therapeutics's forecast annual revenue growth rate of -8.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Adaptimmune Therapeutics's revenue in 2025 is $179,639,000.On average, 3 Wall Street analysts forecast ADAP's revenue for 2025 to be $69,590,355,423, with the lowest ADAP revenue forecast at $47,865,136,716, and the highest ADAP revenue forecast at $100,189,501,398. On average, 3 Wall Street analysts forecast ADAP's revenue for 2026 to be $123,498,668,414, with the lowest ADAP revenue forecast at $114,459,348,954, and the highest ADAP revenue forecast at $132,631,816,136.
In 2027, ADAP is forecast to generate $238,912,203,096 in revenue, with the lowest revenue forecast at $238,912,203,096 and the highest revenue forecast at $238,912,203,096.